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Background: Cancer metastasis is the main contributor to breast cancer fatalities as women with the metastatic
disease have poorer survival outcomes than women with localised breast cancers. There is an urgent need to
develop appropriate prognostic methods to stratify patients based on the propensities of their cancers to
metastasise. The insulin-like growth factor (IGF)-I: IGF binding protein (IGFBP):vitronectin complexes have been
shown to stimulate changes in gene expression favouring increased breast cancer cell survival and a migratory
phenotype. We therefore investigated the prognostic potential of these IGF- and extracellular matrix (ECM)
interaction-induced proteins in the early identification of breast cancers with a propensity to metastasise using
patient-derived tissue microarrays.
Methods: Semiquantitative immunohistochemistry analyses were performed to compare the extracellular and
subcellular distribution of IGF- and ECM-induced signalling proteins among matched normal, primary cancer and
metastatic cancer formalin-fixed paraffin-embedded breast tissue samples.
Results: The IGF- and ECM-induced signalling proteins were differentially expressed between subcellular and
extracellular localisations. Vitronectin and IGFBP-5 immunoreactivity was lower while β1 integrin immunoreactivity
was higher in the stroma surrounding metastatic cancer tissues, as compared to normal breast and primary
cancer stromal tissues. Similarly, immunoreactive stratifin was found to be increased in the stroma of primary as
well as metastatic breast tissues. Immunoreactive fibronectin and β1 integrin was found to be highly expressed at
the leading edge of tumours. Based on the immunoreactivity it was apparent that the cell signalling proteins
AKT1 and ERK1/2 shuffled from the nucleus to the cytoplasm with tumour progression.
Conclusion: This is the first in-depth, compartmentalised analysis of the distribution of IGF- and ECM-induced
signalling proteins in metastatic breast cancers. This study has provided insights into the changing pattern of
cellular localisation and expression of IGF- and ECM-induced signalling proteins in different stages of breast
cancer. The differential distribution of these biomarkers could provide important prognostic and predictive
indicators that may assist the clinical management of breast disease, namely in the early identification of cancers
with a propensity to metastasise, and/or recur following adjuvant therapy.
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Experimental and clinical evidence has implicated a role
for the insulin-like growth factor (IGF) axis in cancer
progression [1]. In fact a number of inhibitors of, and anti-
bodies directed against, the IGF type I receptor (IGF-IR)
have been reported to show anti-tumour activity in vitro
and in vivo, and are currently in clinical trials [2]. These
studies, combined with many others, have highlighted the
complexity of the dysregulation of the IGF system in can-
cers. Simply targeting the IGF-IR or the IGF system in iso-
lation may therefore not be the most efficacious strategy
for treating this disease; more complex therapeutic ap-
proaches to target the IGF system and prevent tumorigen-
esis and, in particular, metastasis, are likely to be required.
Cancer metastasis is the main contributor to breast
cancer fatalities [3]. Women with metastatic breast can-
cers have considerably poorer survival outcomes than
women whose cancers are localised to the breast [4,5].
Adjuvant systemic therapies for patients with breast can-
cer metastasis remain palliative [3]. Understanding the
processes underpinning the progression of breast cancer,
identifying patients likely to develop metastases and
developing strategies to prevent the secondary spread of
cancers are of significant clinical and financial relevance.
There has also been a growing urgency to create cost-
effective and appropriate prognostic methods that can
accurately resolve those patients with a poor prognosis
that require more intense treatment regimes. The prog-
nostic methods currently available are unable to ad-
equately address this issue [6,7].
A critical component that is often overlooked during
the identification and analysis of prognostic biomarkers,
and one which may explain the inability to develop
adequate prognostic techniques thus far, is the interplay
between tumour cells, the surrounding microenviron-
ment and the growth factors present in this milieu. Cel-
lular attachment and interactions with the extracellular
matrix (ECM) regulate biological responses vital for
tumour progression. Considerable evidence indicates
that interactions between proteins required for IGF-
induced signalling events and those within the ECM
contribute to processes leading to cancer progression.
Studies by Kricker et al. [8] found that IGF-I stimulates
migration of MCF-7 breast cancer cells when bound to
the ECM protein vitronectin (VN) indirectly through the
presence of IGF binding proteins (IGFBPs). The pres-
ence of function blocking antibodies against IGF-IR and
VN-binding integrins abolished the enhanced migration
of these cells [9], while, the overexpression of total-akt/
protein kinase B (AKT) and phosphorylated-akt/protein
kinase B (P-AKT) enhanced IGF-I: IGFBP:VN-stimu-
lated migration [9]. Gene microarray technology has also
been applied to elucidate the molecular mechanisms
involved in IGF-I: IGFBP:VN-stimulated migration ofbreast cancer cells in in vitro cell based assays [10]. These
studies have identified a number of genes, including Stra-
tifin (SFN), enhancer-of-split and hairy-related protein 2
(Sharp-2), Tissue Factor, Claudin-1 (CLDN1), that are
uniquely regulated by the IGF-I: IGFBP:VN complex. The
genes are known for their roles in migration, invasion as
well as cell survival. However, to date the effects of IGF
and ECM protein interactions on the dissemination and
progression of breast cancer in vivo are unclear. Given
this, we chose to investigate the clinical relevance of pro-
teins required for IGF-induced signalling events and those
within the ECM for the development and progression of




Ethical approval for this work was obtained from the
Queensland University of Technology, Australia (08000
00565), the Princess Alexandra Hospital Australia (2005/
163), Royal Brisbane & Women’s Hospital, Australia
(PR07/004) and Queensland Institute of Medical Re-
search, Australia (P716). This project utilised archived
human tissue samples collected between January 1970
and June 2005. The human tissue samples and patients
records were collected as a routine part of clinical man-
agement of the breast disease. Patient consent was not
required. All patient clinical information was obtained
from the Queensland Cancer Registery (Australia) in a
de-identified and encoded manner. Approval to use
these samples and data was sought from Dr Glenn
Francis and Queensland Health (Australia).
Selection of patient specimen
This project utilised formalin-fixed paraffin-embedded
(FFPE) archival breast carcinoma specimens from 91
women who presented with metastatic breast carcinoma
(refer to Additional file 1 and Additional file 2 for fur-
ther details). These specimens were surgically removed
from the breast and axillary lymph nodes (LNs). For
each patient, tissues containing normal breast epithelial
ducts, primary breast carcinoma and LN metastasis were
identified from haematoxylin and eosin stained sections.
Cores containing DCIS tissues were omitted due to low
samples numbers. Details on the selected patient cohort
are provided in Additional file 3 and Additional file 4.
Tissue microarray (TMA) construction
See details of TMA construction in Additional file 5.
Where possible, the TMA cores were obtained from the
leading edge of the tumour, thought to be where interac-
tions between ligands in the ECM and the cancer cells
were more likely to have functional significance [11].
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The candidate molecules selected for this investigation
were: IGFBP-5, VN, fibronectin (FN), αv integrin, β1 integ-
rin, total-akt/protein kinase B 1 (Total-AKT1), P-AKT
(Ser473), extracellular signal-related kinase-1 and extracel-
lular signal-related kinase-2 (ERK1/2), phosphorylated-
extracellular signal-related kinase-1 and extracellular
signal-related kinase-2 (P-ERK1/2) (Thr202/Thr204),
SHARP-2 and SFN. Oestrogen receptor (ER), progester-
one receptor (PR) and HER2 were also selected for
investigation.
Immunohistochemistry (IHC)
The candidate markers were detected using commercially
documented antibodies based upon prior independent
validation for immunohistological applications in FFPE
sections. Refer to Additional file 6 and Additional file 7
for specific details on the antibodies and IHC optimisation
protocols, respectively.
Distiller: a secure, web based, flexible information
management system
The virtual TMA slide files created using the NanoZoomer
2.0 series (Hamamatsu®, Hamamatsu City, Shizuoka
Pref., Japan) digital slide scanner and scanning software
NDP.scan 2.0 series (Hamamatsu®) were uploaded into
Distiller (SlidePath Ltd Digital Pathology Solutions,
Santry, Dublin, Ireland) for image analysis. Distiller was
used to facilitate the integration of clinical records, re-
search data, digital TMA slides and different data types
into a hierarchical database (see Additional file 8 for
information).
Scoring immunohistochemical immunoreactivity
The digital TMA images were examined and scored by
trained anatomical pathology (AP) registrars without prior
knowledge of the patient’s clinical data (i.e. ‘blind’) within
the Distiller framework. If there were no pathologists
available to score the TMAs, they were scored by Helen C
Plant. Qualitative differences in the immunoreactivity of
the proteins within the cytoplasm, nucleus and membrane
of the cells were determined for each TMA core contain-
ing either normal breast epithelial ducts (normal), primary
breast carcinoma (primary) or metastatic breast carcin-
oma (LN met). Qualitative differences in staining of the
stromal cells and ECM adjacent to normal, primary and
LN met tissue were also recorded. Protein immunoreac-
tivity was evaluated semiquantitatively using five scoring
methods. These included: presence of protein immunore-
activity; intensity of protein immunoreactivity; percentage
of cells with protein immunoreactivity; percentage class
and quickscore (Q score) scoring method [12]. Details on
these scoring methods and data consolidation strategies
are listed in Additional file 9.Statistical data analysis
PASW Statistics 18 version 18.0.2 (SPSS, IBM Corpor-
ation, Chicago, Illinois, USA) was used to evaluate statis-
tical confidence of the data. The choice of test of
association for the five scoring methods of protein immu-
noreactivity depended on the measurement scale of the
scoring method. Presence is a binary outcome (present/
absent) hence Pearson’s χ2 test of independence was used.
For the ordinal scaled intensity, a Kruskal-Wallis test was
employed to determine if any of the groups demonstrated
differences. No protected rank-based non-parametric test
exists for the post-hoc evaluation of pair-wise differences.
Instead, the Mann-Whitney U test was used to evaluate
between-groups differences with inflation of family-wise
type I error being controlled using Bonferroni corrections.
Finally, the remaining three measures of protein immuno-
reactivity, percentage, percentage class and Q score were all
treated as quantitative outcomes and one-way Analysis of
Variance (ANOVA) followed by Tukey’s HSDs for post-
hoc testing was used to detect differences. As no rank-
based non-parametric method exists to test for effect
modification (i.e. interactions), interactions were probed
by running the (one-way) Kruskal-Wallis tests for each
strata of a potential effect modifier. For all tests, a
significance level (α) of 0.05 was used, with the exception
of where the Mann-Whitney U was used to test for post-
hoc differences, where αFW = α/k = 0.05/6 = 0.008 was used
(k = 6 represents the number of pairwise comparisons).
Results
The capability of the ECM and IGF system proteins to
regulate cell function, and consequently tumorigenesis, is
highly influenced by their spatial arrangement within and
around the cell. It was observed that proteins required for
IGF- and ECM-induced signalling events are differentially
expressed between subcellular and extracellular localisa-
tions and that the interpretation of the protein immunore-
activity data is influenced by the scoring method applied.
The results described below will only refer to the results
obtained for the Q score scoring method [12]. The Q score
values (x), including the standard deviation (SD) and sam-
ple numbers (n) for each protein across the tissue types
and cellular localisation are outlined in Table 1.
Changes in ECM proteins
The most obvious differences in the immunoreactive dis-
tribution between normal breast, primary and metastatic
cancer tissue samples was observed in proteins located in
the extracellular space surrounding normal breast ducts
and primary and metastatic tumours. These findings are
intriguing given that the processes occurring during nor-
mal breast development are tightly regulated by the ECM
and that the ability of the ECM to provide homeostatic
regulation is disrupted during the development and
Table 1 Q-score values for immunoreactivity of each protein across tissue types and cellular localisation
Protein Cellular localisation Type of breast tissue x SD n
αv integrin Stroma Normal 1.29 1.25 7
αv integrin Stroma Primary 0.34 0.83 32
αv integrin Stroma LN Metastasis 0.16 0.69 19
VN Cytoplasm Normal 0.78 1.65 23
VN Cytoplasm Primary 2.21 2.69 86
VN Cytoplasm LN Metastasis 2.44 2.38 68
VN Stroma Normal 7.13 3.75 23
VN Stroma Primary 2.84 2.73 86
VN Stroma LN Metastasis 0.84 2.13 68
IGFBP-5 Stroma Normal 13.00 4.52 6
IGFBP-5 Stroma Primary 8.49 4.18 35
IGFBP-5 Stroma LN Metastasis 4.17 4.57 23
β1 integrin Stroma Normal 4.79 3.62 14
β1 integrin Stroma Primary 9.71 4.36 84
β1 integrin Stroma LN Metastasis 14.47 4.21 68
FN Stroma Normal 4.08 1.88 12
FN Stroma Primary 8.66 4.42 85
FN Stroma LN Metastasis 7.36 5.05 67
SFN Nucleus Normal 1.07 1.73 14
SFN Nucleus Primary 3.40 3.27 82
SFN Nucleus LN Metastasis 3.88 2.84 68
SFN Cytoplasm Normal 2.93 2.30 14
SFN Cytoplasm Primary 5.43 2.20 82
SFN Cytoplasm LN Metastasis 5.75 1.93 68
SFN Stroma Normal 0.00 0.00 14
SFN Stroma Primary 0.78 0.89 82
SFN Stroma LN Metastasis 1.12 0.95 68
SHARP-2 Nucleus Normal 8.29 3.71 14
SHARP-2 Nucleus Primary 5.76 5.61 86
SHARP-2 Nucleus LN Metastasis 3.33 3.69 70
SHARP-2 Cytoplasm Normal 6.36 4.50 14
SHARP-2 Cytoplasm Primary 7.90 3.72 86
SHARP-2 Cytoplasm LN Metastasis 8.80 4.57 70
T-AKT1 Nucleus Normal 5.69 6.91 13
T-AKT1 Nucleus Primary 3.39 4.08 85
T-AKT1 Nucleus LN Metastasis 2.59 2.93 68
T-AKT1 Cytoplasm Normal 7.54 3.76 13
T-AKT1 Cytoplasm Primary 8.78 3.95 85
T-AKT1 Cytoplasm LN Metastasis 9.37 3.67 68
P-AKT Nucleus Normal 13.50 6.21 16
P-AKT Nucleus Primary 11.51 5.52 86
P-AKT Nucleus LN Metastasis 9.32 5.44 68
P-AKT Cytoplasm Normal 1.19 1.47 16
P-AKT Cytoplasm Primary 2.19 2.12 86
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Table 1 Q-score values for immunoreactivity of each protein across tissue types and cellular localisation (Continued)
P-AKT Cytoplasm LN Metastasis 2.00 2.32 68
ERK1/2 Nucleus Normal 2.67 2.92 15
ERK1/2 Nucleus Primary 1.77 2.76 84
ERK1/2 Nucleus LN Metastasis 0.75 1.82 67
ERK1/2 Cytoplasm Normal 3.73 3.31 15
ERK1/2 Cytoplasm Primary 6.18 4.20 84
ERK1/2 Cytoplasm LN Metastasis 5.42 3.73 67
P-ERK1/2 Nucleus Normal 1.83 2.79 12
P-ERK1/2 Nucleus Primary 1.89 3.47 76
P-ERK1/2 Nucleus LN Metastasis 0.41 1.03 64
P-ERK1/2 Cytoplasm Normal 9.67 4.46 12
P-ERK1/2 Cytoplasm Primary 10.08 4.27 76
P-ERK1/2 Cytoplasm LN Metastasis 9.78 3.95 64
x = Q score; SD = standard deviation; n = sample size; LN = lymph node; P = phosphorylated; T = Total.
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munoreactivity of key ECM molecules, IGF regulators and
integrins decreased with tumour development and/or pro-
gression. Significant differences in the immunoreactivity
of stromal VN (p < 0.001), IGFBP-5 (p < 0.001) and β1 in-
tegrin (p < 0.001) within the tissue types examined were
detected (Figures 1A-C and 2Ai, respectively). Stromal
IGFBP-5 and VN immunoreactivity in the metastatic can-
cer tissues was found to be significantly less than stromal
IGFBP-5 and VN immunoreactivity in the normal breast
tissues (p < 0.001 and p < 0.001, respectively) and primary
cancer tissues (p < 0.01 and p < 0.001, respectively)
(Figure 1C and 1A, respectively). Additionally, stromal
VN immunoreactivity was greater within normal breast
tissue as compared to the immunoreactivity detected in
primary cancer tissues (p < 0.001) (Figure 1A). Despite
not reaching statistical significance (p = 0.054), compar-
able trends were observed for stromal αv integrin stain-
ing with increasing invasiveness of the tissue types
examined (Figure 1B).
In contrast, the β1 integrin immunoreactivity detected
in the stroma of metastatic cancer tissue was signifi-
cantly higher than the β1 integrin immunoreactivity de-
tected in the stroma in the normal breast (p < 0.001) and
primary cancer (p < 0.001) tissue samples (Figure 2Ai).
In the primary cancer tissues, stromal reactivity of the β1
integrin was significantly greater than within the normal
breast tissues (p < 0.001) (Figure 2Ai). No statistically
significant differences in FN reactivity between the vari-
ous tissue types were examined (p = 0.094) (Figure 2Bi).
These findings suggest that VN, IGFBP-5 and αv integrin
reactivity in the stroma decreased while stromal β1 in-
tegrin immunoreactivity increased with tumour progres-
sion. Figure 2Bi reveals trends, albeit not statistically
significant, which suggest that the stromal localisation of
FN differs to that of the other ECM proteins analysed.Tumour leading edge
Given these findings, we next investigated whether the
distribution of β1 integrin and FN immunoreactivity
within the stroma could be functionally associated with
cancer invasion. FN immunoreactivity was observed
throughout the stroma immediately adjacent and distal
to the leading edges of each tumour (Figure 2Bii - v).
There was also a higher presence of FN immunoreac-
tivity both inside tumour cells at the leading edges and
in the stroma directly surrounding the leading edges
(Figure 2Bii - v). In particular, greater membrane and
cytoplasmic FN was associated with tumour cells at the
leading edge and in close proximity to the leading edge, in
contrast to the cells within the middle of the tumour. Par-
alleling the distribution of FN, β1 integrin immunoreactiv-
ity was detected throughout the stroma immediately
surrounding and distant to the leading edges of the
tumours (Figure 2Aii - ix). There were many instances
where the β1 integrin was also detected both inside
tumour cells at the leading edges and within the stroma of
the leading edges of tumours (Figure 2Aii - ix). Again,
greater membrane β1 integrin immunoreactivity was ob-
served in tumour cells at the leading edge and in close
proximity to the leading edge, compared to the main bulk
of the tumour. However, there were no obvious differ-
ences between the cytoplasmic expression of β1 integrin
in cells at the leading edge of tumours and those in the
centre of the tumours.
SFN in stroma
Significant differences were evident in the immunoreac-
tivity of SFN in the stroma of the tissue types examined
(p < 0.001) (Figure 3). In particular, SFN immunoreac-
tivity scores within the stroma of normal breast tissue
were significantly lower than the SFN immunoreactivity
scores within stroma of primary (p < 0.05) and metastatic
Figure 1 Stromal immunoreactivity of VN, αv integrin and IGFBP-5. Immunoreactivity of VN (A), αv integrin (B) and IGFBP-5 (C) within the stroma
surrounding normal breast (Normal), primary cancer (Primary) and LN metastasis tissues is depicted. Immunoreactivity was evaluated semiquantitatively
using the Q score (intensity x percentage class, score: 0 – 18) method. Intensity of reactivity (score: 0 = negative; 1 =weak; 2 =moderate, and; 3 = strong).
Percentage class (score: 1 = 0-4%; 2 = 5-19%; 3 = 20-39%; 4 = 40-59%; 5 = 60-79%; 6 = 80-100%). Data are displayed using the mean ± 2 standard error (SE).
Asterisks (** and ***) indicate statistically significant differences at p < 0.01 and <0.001, respectively. Scale bar = 30 μm.
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that SFN immunoreactivity increases in the stroma with
tumour development and progression.
Intracellular movement of cell signalling proteins
The occupation of IGF-IR and integrin molecules results
in the recruitment of adapter proteins to the cell mem-
brane and the formation of multiprotein complexes and
facilitates the phosphorylation and activation of signalling
cascades including AKT and MAPK [13]. The phosphoryl-
ation of AKT and MAPK impacts the cellular localisation,
specificity and consequently the protein targets of these
signalling molecules [14,15]. In light of this, the immuno-
reactivity of Total- and Phosphorylated- AKT and ERK1/2
within the cytoplasm and nucleus of cells from normalbreast, primary and metastatic cancers were investigated
to determine their role in the downstream signalling
events during the development and progression of breast
cancer. The intracellular localisation of SHARP-2 and
SFN species uniquely regulated by the IGF-I: IGFBP:VN
complex [10], were also investigated.
Significant differences in nuclear localisation of P-AKT,
ERK1/2 and SHARP-2 reactivity (p < 0.01, p < 0.05 and p <
0.001, respectively) were detected between the normal
breast, primary cancer and metastatic cancer tissues exam-
ined (Figures 4C, D and 5A). More specifically, nuclear
P-AKT, ERK1/2 and SHARP-2 immunoreactivity within
metastatic cancer tissues was lower than that observed
within normal breast tissues (p < 0.05, p < 0.05 and p <
0.01, respectively) (Figures 4C, D and 5A). There was also
Figure 2 Stromal immunoreactivity of β1 integrin and FN. Immunoreactivity of β1 integrin is depicted in A. i) Immunoreactivity of β1 integrin
within the stroma surrounding normal breast (Normal), primary cancer (Primary) and LN metastasis tissues. ii – ix) Representative images
demonstrating distribution of β1 integrin in the stroma and/or cells at the leading edges of Normal (ii and iii), ductal carcinoma in situ (iv and v),
Primary (vi and vii) and LN metastasis (viii and ix) tissues. Immunoreactivity of FN is depicted in B. i) Immunoreactivity of FN within the stroma
surrounding Normal, Primary and LN metastasis tissues. ii – v) Representative images demonstrating distribution of β1 integrin immunoreactivity in the
stroma and/or cells at the leading edges of Primary (ii and iii) and LN metastasis (iv and v) tissues. Immunoreactivity was evaluated semiquantitatively
using the Q score (intensity x percentage class, score: 0 – 18) method. Intensity of reactivity (score: 0 = negative; 1 =weak; 2 =moderate, and; 3 = strong).
Percentage class (score: 1 = 0-4%; 2 = 5-19%; 3 = 20-39%; 4 = 40-59%; 5 = 60-79%; 6 = 80-100%). Data are displayed using the mean ± 2 standard error
(SE). Asterisks (* and ***) indicate statistically significant differences at p < 0.05 and <0.001, respectively. The scale bar for Aii, Aiv, Avi, Aviii, Bii and Biv is
200 μm and for Aiii, Av, Avii, Aix, Biii and Bv is 30 μm.
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static breast tissue than within primary cancer tissues
(p < 0.01). Thus, the nuclear localisation of P-AKT,
ERK1/2 and SHARP-2 decreased with tumour develop-
ment and/or progression. In contrast, Figures 4 and 5
reveal trends, albeit not statistically significant, which
suggest that the cytoplasmic localisation of Total-AKT1,
P-AKT and SHARP-2 may increase with tumour develop-
ment and/or progression. Additionally, in many of the
primary cancer and metastatic (data not shown) tissues in
this study there was more nuclear immunoreactivity for
SHARP-2 at the periphery of the tumour than was evident
in the centre of the tumour (Figure 5B).
We further observed that differences in nuclear and
cytoplasmic SFN reactivity (p < 0.05 and p < 0.001,
respectively) between the normal breast, primary cancer
and metastatic cancer tissues were significant (Figure 4A).
In particular, nuclear and cytoplasmic SFN within normalbreast tissue was lower than the amount of nuclear and
cytoplasmic SFN within primary cancer (p < 0.05 and p <
0.001, respectively) and metastatic cancer tissues (p < 0.01
and p < 0.001, respectively). There were no significant
differences in nuclear and cytoplasmic immunoreactivity
of SFN between primary and metastatic tumours.
Internalisation of ECM proteins
Our data also provides evidence that ECM molecules are
internalised during breast cancer development and me-
tastasis. Statistically significant differences in cytoplasmic
(p < 0.05) VN immunoreactivity was observed between
the specific tissue types examined in this study (Figure 6).
In particular, lower cytoplasmic VN immunoreactivity
was observed in normal breast tissues than cytoplasmic
VN immunoreactivity within metastatic cancer tissues
(p < 0.05) (Figure 6). As such, our data indicates that VN
redistributes to the cytoplasm with tumour progression.
Figure 3 Stromal immunoreactivity of SFN. Immunoreactivity of SFN within the stroma surrounding normal breast (Normal), primary cancer
(Primary) and LN metastasis tissues is depicted. Immunoreactivity was evaluated semiquantitatively using the Q score (intensity x percentage class,
score: 0 – 18) method. Intensity of reactivity (score: 0 = negative; 1 = weak; 2 =moderate, and; 3 = strong). Percentage class (score: 1 = 0-4%; 2 = 5-
19%; 3 = 20-39%; 4 = 40-59%; 5 = 60-79%; 6 = 80-100%). Data are displayed using the mean ± 2 standard error (SE). Asterisks (* and ***) indicate
statistically significant differences at p < 0.05 and <0.001, respectively. Scale bar = 30 μm.
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In this study a change in the immunoreactivity of key
ECM molecules, IGF regulators and integrins was ob-
served with breast tumour progression. These observa-
tions suggest that the ECM surrounding normal breast
ductal structures is remodelled during tumour develop-
ment and progression. The ECM protein FN and the
cell surface β1 integrin (the FN-binding receptor) were
found to be highly expressed along the leading edge of
many primary tumours in the present study. Interest-
ingly, FN is implicated in epithelial-to-mesenchymal
transition (EMT) [16] and both the β1 integrin and FN
are required in the formation of lamellipodia, filopodia
and invadopodia [17,18]; potentially supporting their
role in ECM remodelling and subsequent tumour cell
invasion [19]. Indeed, the β1 integrin has been reported
to be more highly expressed in primary tumours with
LN metastases [20] and with poor survival outcomes
[21]. This fits in well with our findings that suggest an
increase in β1 integrin immunoreactivity with increas-
ing invasiveness. Various proteases, including matrix
metalloproteinases (MMPs) have been implicated in
ECM remodelling events that allow cancer cells to
migrate [22]. It has been shown that the expression,
activity and/or internalisation of MMPs is regulated by
integrin-ECM interactions in endothelial cells [23].
Integrins, such as the αvβ3 integrin, cooperate with
MMPs to regulate breast cancer cell migration [24].
Interestingly, IGF-I:VN: IGFBP-5-stimulated breast cell
migration, which requires the IGF-IR and VN-binding
integrins [9], can regulate the gene expression of prote-
ases such as MMP13, MMP7, ADAMTS5, CPM and
protease inhibitors such as SERPINE1 and TRP1 ([10]
and supplementary data from [10]).The data we report here has also provided evidence
that ECM molecules and their associated membrane-
bound receptors, the integrins, are internalised during
breast cancer development and metastasis. Step-wise
increases in cytoplasmic and concomitant decreases in
stromal immunoreactivity of VN and the αv integrin
(data not shown) were evident between normal breast,
primary and metastatic cancer tissues. As described
previously, VN can be internalised by integrin receptor-
mediated endocytosis and degraded within the lyso-
somes [25]. There is also evidence indicating that the
VN-binding αv integrin can be recycled to the cell mem-
brane through intracellular signals [26]. This decrease in
the stromal VN and the concomitant increase in the
cytoplasmic VN with breast cancer progression suggests
a potential re-shuffling or trafficking of VN from the
tumour stroma to the tumour cell cytoplasm with in-
creasing invasiveness of the tumour-type.
Given the importance of the phosphoinositol 3-kinase
(PI3K) and mitogen-activated protein kinase (MAPK)
signalling pathways in IGF-I: IGFBP:VN-stimulated mi-
gration of breast cancer cells in vitro [9], and in IGF-I-
stimulated ECM re-modelling [27] and EMT events
[27,28], protein intermediates within these pathways
were also investigated. Decreases in the nuclear immu-
noreactivity and increases in the cytoplasmic immunore-
activity in breast cancer tissues were observed in this
study. We propose a number of explanations for these
findings: namely, the preferential activation of substrates
in the cytoplasm (of cancer cells) rather than in the nu-
cleus; enzyme-mediated dephosphorylation; and protein
internalisation. Both AKT1 and MAPK contain transpor-
tation signals which potentially enable their movement
throughout a cell [29,30]. Defects in these transportation
Figure 4 (See legend on next page.)
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(See figure on previous page.)
Figure 4 Tissue localisation. Differential localisation of SFN (A), Total-AKT1 (B), P-AKT (C), ERK1/2 (D) and P-ERK1/2 (E) is depicted. Nuclear (open
circles) and cytoplasmic (closed triangles) immunoreactivity within normal breast (Normal), primary cancer (Primary) and LN metastasis tissues was
determined. Antibody immunoreactivity was evaluated semiquantitatively using the Q score (intensity x percentage class, score: 0 – 18) method.
Intensity of reactivity (score: 0 = negative; 1 = weak; 2 =moderate, and; 3 = strong). Percentage class (score: 1 = 0-4%; 2 = 5-19%; 3 = 20-39%; 4 =
40-59%; 5 = 60-79%; 6 = 80-100%). Data are displayed using the mean ± 2 standard error (SE). Asterisks (*, ** and ***) indicate statistically significant
differences at p < 0.05, <0.01 and <0.001, respectively.
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http://www.biomedcentral.com/1471-2407/14/627signals during cancer tumorigenesis might explain the
results of this study. Ras homolog gene family member
B (RhoB), which has been shown to influence the traf-
ficking of Total- and P-AKT in primary human endothe-
lial cells [31], may impede the import of Total- and
P-AKT into or promote the export of Total- and P-AKT
from the nucleus of breast cancer cells; resulting in an
accumulation of AKT in cytoplasmic compartments.
Phospho-kinases, such as MAPK, are not necessarily
required to enter the nucleus to regulate gene transcrip-
tion. In fact, the activation of transcription factors in the
cytoplasm and their movement into the nucleus for tran-
scriptional control [32] has been reported. The duration
and strength of AKT and MAPK signalling in breast epi-
thelial cells can also be regulated in different subcellular
locations through the action of various cytoplasmic and
nuclear phosphatases [33]. Indeed, phosphatase and ten-
sin homolog (PTEN), a dual lipid and protein phosphat-
ase, can be localised to the cell nucleus [34], and if
functional, may therefore de-phosphorylate nuclear
AKT. As discussed by Tzivion et al. [35], the ability of a
protein to interact with modifying enzymes, such as
phosphatases, can be influenced by the presence of
14-3-3 proteins.
Intriguingly, 14-3-3 proteins, including SFN, have been
shown to regulate the cytoplasmic sequestration and
nuclear retention of cell cycle regulators, many of which
are associated with and downstream of the PI3K path-
way [36]. It is highly likely that 14-3-3 proteins, such as
SFN, may regulate similar sequestration events for P-
AKT itself. It was intriguing to find that the increases in
the nuclear and cytoplasmic immunoreactivity of SFN
with breast cancer development and progression as mea-
sured in this study correlated with the increase in
mRNA expression of SFN reported by Kashyap et al.
[10]. In contrast, other studies have reported the down-
regulation of SFN expression in breast cancers [37,38].
However, Neal et al. [39] showed that overexpression of
SFN reduces the overall and disease-free survival of
breast cancer patients and is able to predict which pa-
tients have a high susceptibility to develop metastasis.
Interestingly, it has been proposed that 14-3-3 proteins
are important regulators of external environmental sig-
nals by eliciting positive and negative effects on the IGF
signalling pathway. The ability of 14-3-3 proteins to bind
phospho-serine enables them to bind to the IGF-IR [40].Yang et al. [41] have shown that SFN can also bind to
and inhibit the activity of AKT, preventing AKT-
mediated cellular events. They also indicate that SFN ex-
pression was inversely correlated with P-AKT expression
[41]; this supports our findings of decreases in nuclear
P-AKT and increases in intracellular SFN with tumour
development and progression.
We were intrigued to find that SFN was differentially
expressed within the stroma surrounding the tissue types
examined. Although previous reports of SFN expression
have been limited to the cytoplasm of malignant breast
cells [38], in vitro evidence indicates that SFN can be ex-
creted by keratinocytes into the pericellular matrix [42].
Extracellular SFN is a key regulator of MMP function
and ECM degradation. Studies have shown that follow-
ing the release of SFN from keratinocytes, MMP-1
mRNA [43] and MMP-1 protein synthesis [44] increases
in dermal fibroblasts. Increases in mRNA encoding the
β1 integrin have also been observed in dermal fibroblasts
after treatment with SFN, or in co-cultures with kerati-
nocytes known to release SFN [45]. Under the same
conditions the expression of many ECM molecules, in-
cluding collagen type I, FN and α1 integrin, decreases.
This collective evidence suggests that it is highly likely
that SFN may mediate similar functions regulating the
degradation of ECM during epithelial tumour develop-
ment and progression.
We also observed step-wise increases in cytoplasmic
and decreases in nuclear immunoreactivity of SHARP-2
between the normal breast, primary and metastatic can-
cer tissues; this may be explained by nucleocytoplasmic
shuttling events. SHARP-2 is known to possess a func-
tional nuclear export sequence (NES) and two nuclear
localisation signal (NLS) motifs [46]. A study by Ivanova
et al. [46] suggests that SHARP-2 may be required in
the nucleus of proliferating and differentiating cells to
regulate gene transcription after stimulation by an exter-
nal factor. They also propose that SHARP-2 may be se-
questered in the cytoplasm following cell differentiation.
In summary, we have reported changes in the tem-
poral and spatial distribution of IGF- and ECM-induced
signalling proteins that occur during breast cancer
metastasis. Specifically, our findings provide further evi-
dence that the ECM surrounding normal breast ductal
structures is remodelled during tumour development
and progression, and that FN and the β1 integrin are
Figure 5 (See legend on next page.)
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(See figure on previous page.)
Figure 5 SHARP-2 immunoreactivity. Immunoreactivity of SHARP-2 within the nucleus (open circles) and cytoplasm (closed triangles) of cells from
normal breast (Normal), primary cancer (Primary) and LN metastasis tissues is depicted in A. Immunoreactivity was evaluated semiquantitatively using
the Q score (intensity x percentage class, score: 0 – 18) method. Intensity of reactivity (score: 0 = negative; 1 =weak; 2 =moderate, and; 3 = strong).
Percentage class (score: 1 = 0-4%; 2 = 5-19%; 3 = 20-39%; 4 = 40-59%; 5 = 60-79%; 6 = 80-100%). Data are displayed using the mean ± 2 standard error
(SE). Asterisks (**) indicate statistically significant differences at p < 0.01. Representative images demonstrating the distribution of SHARP-2 in the cancer
cells of primary cancer tissue samples is depicted in B (i-iv). The scale bar for A, Bii and Biv is 30 μm and for Bi and Biii is 200 μm.
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http://www.biomedcentral.com/1471-2407/14/627important for the formation of invadopodia and for the
epithelial-to-mesenchymal transition events (shown by
others [47]) to support dissemination. Analysis of stro-
mal and subcellular SFN immunoreactivity suggested a
causal relationship in ECM remodelling events and the
localisation and activity of proteins important for IGF-
and ECM-induced signalling cascades. It also appears
plausible that in cells at the leading edge of tumours,
SHARP-2 moves into the nucleus to repress the tran-
scription of genes associated with the hypoxic response.
Collectively the above data highlight the possibility
that there are broader biological implications of, andFigure 6 VN immunoreactivity. Immunoreactivity of VN within the cell c
breast (Normal), primary cancer (Primary) and LN metastasis tissues is depic
score (intensity x percentage class, score: 0 – 18) method. Intensity of reactivi
Percentage class (score: 1 = 0-4%; 2 = 5-19%; 3 = 20-39%; 4 = 40-59%; 5 = 60-
error (SE). Asterisks (* and ***) indicate statistically significant differences atexplanations for, the differential immunoreactivity of
IGF signalling and ECM components in the stroma and/
or in subcellular locations within normal breast, primary
breast cancer and metastatic breast cancers. This is
highly pertinent given that protein function and protein
localisation are closely correlated. Studies have also
shown that accounting for protein localisation can be an
essential requirement to identifying correlations with
other proteins when applying the IHC technique [48].
To date, very few studies have evaluated the prognostic
significance of differential protein distribution within
diagnostic breast cancer tissue samples. Early studies do,ytoplasm (open circles) and the stroma (closed triangles) of normal
ted. Immunoreactivity was evaluated semiquantitatively using the Q
ty (score: 0 = negative; 1 = weak; 2 =moderate, and; 3 = strong).
79%; 6 = 80-100%). Data are displayed using the mean ± 2 standard
p < 0.05 and <0.001, respectively. Scale bar = 30 μm.
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http://www.biomedcentral.com/1471-2407/14/627however, suggest that specific locations of specific pro-
teins associated with the IGF signalling cascade and the
ECM have shown potential as markers for patient prog-
nosis and therapeutic response [49,50]. We argue that to
date the potential of many molecular species to serve as
markers of patient prognosis and therapeutic response is
being missed by overlooking their subcellular/extracellu-
lar distribution. In view of this, we recommend a more
complete analysis of protein localisation within diagnos-
tic pathology and improvements to reporting and inclu-
sion of protein localisation in routine pathological
examinations as our data indicates the potential role of
protein localisation in the progression of disease.Conclusions
There is potential that the cellular and ECM events out-
lined herein could be manipulated to provide clinical
benefits and improve the clinical management of breast
cancer. In particular, may lead to early prognostic and
predictive identification of patients with poor survival
outcomes. However, prior to this occurring, the prog-
nostic significance of the cellular and ECM events
reported in this study must be identified.Additional files
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